Sonelokimab Improves Psoriatic Arthritis Symptoms

Sonelokimab Shows Promise in Psoriatic Arthritis Treatment: A Summary

A phase 2 trial suggests that sonelokimab, a nanobody targeting both IL-17A and IL-17F, significantly improved signs and symptoms of psoriatic arthritis (PsA). Here’s a breakdown of the key findings:

Key Results (at week 12):

* Primary Endpoint (ACR50 Response):

* 46.3% of patients on 60mg with induction (WI) achieved ACR50.
* 46.5% of patients on 120mg with induction (WI) achieved ACR50.
* The 120mg without induction (NI) group also met the primary endpoint.
* Compared to only 20% in the placebo group.
* Secondary Endpoint (ACR20 Response):

* 78.0% in the 60mg WI group.
* 72.1% in the 120mg WI group.
* Compared to 37.5% in the placebo group.
* Secondary Endpoint (PASI 90):

* 76.9% in the 60mg WI group.
* 59.3% in the 120mg WI group.
* Compared to 15.4% in the placebo group.
* Exploratory & Secondary Endpoints: Improvements were also seen in ACR70 + PASI 100 and minimal disease activity, with up to 48% and 61% achieving these respectively in certain groups.

Study Design:

* Randomized, double-blind, placebo-controlled trial.

* 207 participants with active PsA.
* Treatment Groups:

* Sonelokimab 120mg Q4W with induction (WI)
* Sonelokimab 60mg Q4W with induction (WI)
* Sonelokimab 60mg Q4W without induction (NI) – placebo initially, then switched to sonelokimab.
* Adalimumab (reference arm)

Why Sonelokimab Might Be Effective:

Researchers suggest that the smaller size of nanobodies (around 150 kDa) compared to customary antibodies may allow for better delivery and concentration in affected tissues, even those with limited blood supply like entheses.

Safety:

* Sonelokimab was well-tolerated.
* The most common adverse events were nasopharyngitis and upper respiratory tract infection.

Source: The findings are based on a study published in HCPLive.com and referenced with superscript 1 throughout the text.